Diligence memo · auto-generated · as of July 2, 2026
Gaingels Glyphic Bio LLC
Gaingels Glyphic Bio LLC looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Gaingels Glyphic Bio LLC operates in Biotech / Pharma, based in BURLINGTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Gaingels Glyphic Bio LLC has raised $147K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $147K on 2022-09-27.
Most recent recorded round closed around 2022-09-27.
Valuation (modeled)modeled
Provath models Gaingels Glyphic Bio LLC at approximately $1.9M (range $80K–$11M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.92× the median modeled value of Pre-Seed Biotech / Pharma companies in 2022–2024 (28 peers) — value vs value, same stage and era. Within the normal band (92% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 3.8 yr ago; this sector typically re-raises about every 15 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 11% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 15% of those peers.
Closest niche peers: Gaingels Oct Bio LLC, Gaingels Alto Pharmacy LLC, Pyros Pharmaceuticals, Inc., Allander Biotechnologies, Inc., CyMon Bio, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.